Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
News|Articles|November 15, 2017
- Pharmaceutical Technology-11-15-2017
- Volume 2017 ebook
- Issue 2
Designing and Operating Flexible, High-Containment Vaccine Manufacturing
Author(s)Thomas Page
A new facility type integrates next-generation mobile cleanroom systems.
Advertisement
Facilities for advanced therapies should be configurable to flexibly segregate production for late-stage and commercial multiproduct operation. Efficient design of a flexible and high-containment vaccine manufacturing facility that can meet all the challenges presented by the market requires a design philosophy that includes all the key control concepts: air, people, equipment, product, and liquid and solid waste. This article discusses best practices for such control and describes the use of modular, mobile cleanrooms.
Download the
.
Article Details
Pharmaceutical Technology and BioPharm International
eBook: Vaccine Development and Manufacturing 2017
November 2017
Pages: 26–30
Citation
When referring to this article, please cite it as T. Page, "Designing and Operating Flexible, High-Containment Vaccine Manufacturing," Pharmaceutical Technology and BioPharm International Vaccine Development and Manufacturing 2017 eBook (November 2017).
Articles in this issue
almost 9 years ago
Therapeutic Vaccines Target Cancer and Other Viral-Induced Diseasesalmost 9 years ago
Using Human Challenge Trials to Develop Flu Vaccinesalmost 9 years ago
Making Vaccines Accessiblealmost 9 years ago
Moving to Closed Systems for Aseptic Processingalmost 9 years ago
Cold Chain: Delivering Vaccines to Patientsalmost 9 years ago
Accelerating Vaccine Development and ManufacturingAdvertisement
Related to this article
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Jason Bertola, executive director of Commercial Development for the Advanced Synthesis Platform at Lonza in North America, explains the demand for spray drying and the hurdles involved with scale up, in an interview with PharmTech.
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
Manufacturing Intelligence: Organoids, Organ-on-a-Chip, and the Trust Gap
3
Complying with International Pharmacopoeias
4
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
5